Scarica l'app Stockscreener
7.52
0.40%
0.03
Dopo l'orario di chiusura:
7.52
Precedente Chiudi:
$7.49
Aprire:
$7.56
Volume 24 ore:
895.35K
Relative Volume:
0.49
Capitalizzazione di mercato:
$882.04M
Reddito:
-
Utile/perdita netta:
$-29.07M
Rapporto P/E:
-25.93
EPS:
-0.29
Flusso di cassa netto:
$-31.85M
1 W Prestazione:
+1.35%
1M Prestazione:
+9.62%
6M Prestazione:
+84.77%
1 anno Prestazione:
+173.45%
Intervallo 1D:
$7.37
$7.57
Intervallo di 1 settimana:
$7.055
$7.655
Portata 52W:
$2.36
$8.11
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Nome
Trevi Therapeutics Inc
Settore
Industria
Telefono
203-304-2499
Indirizzo
195 CHURCH STREET, NEW HAVEN, CT
Confronta TRVI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
7.52 | 912.11M | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-05-28 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-10 | Reiterato | Needham | Buy |
| 2025-03-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-30 | Iniziato | Raymond James | Outperform |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-04-12 | Iniziato | B. Riley Securities | Buy |
| 2022-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | BMO Capital Markets | Outperform |
| 2019-06-03 | Iniziato | Needham | Buy |
| 2019-06-03 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | Stifel | Buy |
Mostra tutto
Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie
Trendline Breach Raises Concern for Trevi Therapeutics Inc. InvestorsInsider Buying & Community Shared Stock Ideas - 선데이타임즈
Is This the Dip to Buy in Trevi Therapeutics Inc.Portfolio Risk Summary & Reliable Intraday Trade Alerts - classian.co.kr
Trevi Therapeutics: Optimism Amid Earnings Call Insights - MSN
Healthcare Analysts Offer Insights on Trevi Therapeutics, DENTSPLY SIRONA, and Arrowhead Pharmaceuticals. - AInvest
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q2 2025 Earnings Call Transcript - Insider Monkey
Why Trevi Therapeutics Inc. stock attracts strong analyst attentionForward PE Discount Stocks - classian.co.kr
Trevi Therapeutics (NASDAQ:TRVI) Price Target Lowered to $22.00 at Needham & Company LLC - MarketBeat
JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛
Trevi Therapeutics outlines $204M cash runway into 2029 as Phase III programs advance following positive CORAL data - MSN
Trevi Therapeutics' Promising Developments and Strategic Expansion Bolster Growth Potential. - AInvest
Trevi Therapeutics' Path to Sustainable Growth and Value Creation - AInvest
Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans - uk.finance.yahoo.com
Trevi Therapeutics (TRVI): A High-Potential Biotech Play in Chronic Cough with a Clear Path to Phase 3 and FDA Alignment - AInvest
Trevi Therapeutics Gears Up For Next Phase After Positive Results - Finimize
Summit Therapeutics shares rise 1.53% intraday after Trevi Therapeutics reports positive Phase 2b trial results for Haduvio. - AInvest
Unlocking Long-Term Value: Trevi Therapeutics' Strategic Capital Efficiency and Robust Clinical Data Drive Phase III Momentum - AInvest
Transcript : Trevi Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Promising Phase 2b Results and Strong Financial Position Drive Buy Rating for Trevi Therapeutics - TipRanks
Earnings call transcript: Trevi Therapeutics Q2 2025 shows slight EPS beat - Investing.com Australia
Trevi Therapeutics Inc (TRVI) Q2 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Trevi Therapeutics Inc (TRVI) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial Strength - GuruFocus
Trevi Therapeutics Reports Positive Trial Results and Financial Stability - TipRanks
Trevi Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Trevi Therapeutics Q2 EPS beats estimates - MarketScreener
Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - PR Newswire
Trevi Therapeutics TRVI Q2 2025 Earnings Preview Upside Potential with Positive Share Dynamics - AInvest
Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025 - 富途牛牛
Is Trevi Therapeutics Inc. stock overvalued or undervaluedMassive profits - Jammu Links News
Should I hold or sell Trevi Therapeutics Inc. stock in 2025Free Investment Timing Strategies - Jammu Links News
What is the risk reward ratio of investing in Trevi Therapeutics Inc. stockUnlock daily stock market insights for success - Jammu Links News
What makes Trevi Therapeutics Inc. stock price move sharplyFree Market Dynamics Reports - Jammu Links News
Published on: 2025-08-03 17:59:19 - Jammu Links News
When is Trevi Therapeutics Inc. stock expected to show significant growthFree Buy/Sell Signal Notifications - Jammu Links News
How strong is Trevi Therapeutics Inc. company’s balance sheetUnlock powerful trading alerts for success - Jammu Links News
What analysts say about Trevi Therapeutics Inc. stockUnlock rapid growth potential in your portfolio - Jammu Links News
Why is Trevi Therapeutics Inc. stock attracting strong analyst attentionExceptional market performance - Jammu Links News
What institutional investors are buying Trevi Therapeutics Inc. stockMarket Forecast Recommendation With Low Risk - Jammu Links News
Trevi Therapeutics to Report Second Quarter 2025 Financial Resul - GuruFocus
Trevi Therapeutics Q2 Earnings: Key Updates on Chronic Cough Drug Trials Coming August 7 - Stock Titan
Is it the right time to buy Trevi Therapeutics Inc. stockEntry Signal Growth Plan For Every Investor - Jammu Links News
Trend analysis for Trevi Therapeutics Inc. this weekLow Risk Buy Zone Opportunity Watch Ongoing - metal.it
Has Trevi Therapeutics Inc. formed a bullish divergenceFundamental + Technical Combined Watchlist - Newser
Predicting Trevi Therapeutics Inc. trend using moving averagesRisk Balanced Picks for Safer Trading - Newser
Bullish Candlestick Pattern Forms in Trevi Therapeutics Inc.Weekly Stock Opportunity Radar Scanner Activated - metal.it
Developing predictive dashboards with Trevi Therapeutics Inc. dataDaily Market Entry Strategy with Tools - Newser
Trevi Therapeutics Inc. Earnings Report Breakdown: What Investors Should KnowWeekly Hot Stocks Based on Volume Flow - Newser
Trevi Therapeutics Inc.’s Beta Climbs After Market VolatilityAI Screening for Swing Trade Picks Finds Momentum - metal.it
Why did Trevi Therapeutics' operating expenses surge in Q3 2024? - AInvest
Trevi Therapeutics to Participate in Upcoming August Conferences - PR Newswire
Trevi Therapeutics Leadership Showcases Chronic Cough Treatment Progress at Major August Biotech Conferences - Stock Titan
Trevi Therapeutics Inc Azioni (TRVI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):